Intratect (Human Normal Immunoglobulin)

Intratect is used to provide passive immunity in conditions characterized by deficient or dysfunctional IgG antibodies.

• Primary immunodeficiency diseases: replaces missing IgG, reducing infection frequency and severity.
• Secondary immunodeficiency: restores IgG levels in patients with acquired immune deficiency, improving host defense.
• Idiopathic thrombocytopenic purpura: modulates immune response to increase platelet counts and reduce bleeding risk.
• Chronic inflammatory demyelinating polyneuropathy: attenuates autoimmune attack on peripheral nerves, aiding motor function recovery.
• Kawasaki disease: supplies immunoglobulin to reduce inflammation and prevent coronary artery complications.

• Intratect provides a pooled collection of human IgG antibodies that bind a broad spectrum of pathogens and antigens. The administered IgG replaces deficient endogenous immunoglobulins, neutralizes toxins, facilitates opsonization, and modulates complement activation and Fc‑receptor mediated immune pathways, thereby delivering passive immunity and attenuating autoimmune activity. It also exerts anti‑inflammatory effects by influencing cytokine production and immune‑cell activation.

Intratect may be associated with a range of infusion‑related and systemic adverse reactions.

Common Side Effects

• Headache: mild to moderate intensity during or after infusion.
• Fever and chills: transient rise in temperature and shivering.
• Nausea or vomiting: gastrointestinal discomfort.
• Fatigue: feeling of tiredness post‑infusion.
• Hypertension: temporary increase in blood pressure.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• Aseptic meningitis: severe headache with neck stiffness.
• Thromboembolic events: clot formation leading to stroke or pulmonary embolism.
• Acute renal failure: sudden loss of kidney function.
• Hemolytic anemia: destruction of red blood cells.
• Anaphylaxis: severe allergic reaction with airway compromise.
• Severe hemolysis or disseminated intravascular coagulation.

Prior to initiating Intratect, clinicians should evaluate patient-specific factors and monitor for potential complications.

• Infusion rate: start slowly and adjust to minimize adverse reactions.
• Renal function: assess baseline kidney status and maintain adequate hydration.
• Thrombotic risk: review history of clotting disorders before therapy.
• IgA deficiency: test for anti‑IgA antibodies to avoid severe allergic responses.
• Pregnancy and lactation: use only if potential benefit justifies potential risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other agents, affecting efficacy or safety.

Major Interactions (Avoid)

• Live attenuated vaccines: may be neutralized; avoid concurrent administration.
• High‑dose aspirin or NSAIDs: increase risk of renal impairment during infusion.

Moderate Interactions (Monitor Closely)

• Corticosteroids: may augment immunosuppressive effect, monitor infection signs.
• Anticoagulants: IVIG can alter coagulation parameters; check INR or PT.
• Diuretics: may exacerbate renal stress; monitor fluid balance.
• Plasma protein assays: IVIG can interfere with laboratory measurements; interpret results cautiously.